PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX??? for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Stock Information for PolyPid Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PolyPid Ltd.

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.